Researchers at the Stanford University School of Medicine believe they have taken the first step forward in developing a new technique of creating nerve cells without having to collect stem cells, which may help reduce the amount of controversy involved in the field of stem cell research.

Scientists at the university were able to transform the skin cells of the mouse into functioning nerve cells, and exciting development in the study and research of regenerative medicine, especially in diagnosis of Alzheimer’s, Parkinson’s, and other neural degenerative disease processes.

Stem cell research continues to be a leading field in the 21st century for the treatment of chronic diseases like diabetes and heart disease, conditions caused by birth defects or spinal cord injuries caused by accidents.

Stem cell therapy, neural stem cell therapy, umbilical cord stem cell therapy and stem cell based therapy are leading the news these days, with new developments and discoveries keeping hope alive for those diagnosed with diabetes, heart or brain injuries and conditions. Stem cell therapy possibilities continue to be developed for potential for treatment in skin conditions and anti-aging skin treatment, orthopedic treatments, and cardiac care, treatment of multiple types of cancer like bladder cancer, bone cancer and lung cancer, and in plastic and reconstructive surgeries and procedures.

Facilities such as EmCell Clinic in Kiev, Ukraine and Integra Medical Center in Tamps, Mexico, offer individuals from around the globe alternative medical treatments and procedures for a wide variety of conditions and the best stem cell surgery abroad.

Article Writer

Embryonic stem cells (ES cells) are stem cells derived from the inner cell mass of an early stage embryo known as a blastocyst. Human embryos reach the blastocyst stage 4-5 days post fertilization, at which time they consist of 50-150 cells. Embryonic Stem (ES) cells are pluripotent. This means they are able to differentiate into all derivatives of the three primary germ layers: ectoderm, endoderm, and mesoderm.

Simply defining, embryonic stem cells are stem cells derived from the inner cell mass of an early stage embryo known as a blastocyst. Human embryos reach the blastocyst stage 4-5 days post fertilization, at which time they consist of 50-150 cells. Embryonic stem cells are pluripotent, which means that they have the ability to differentiate into organized masses of tissues or organs.

The results of this experiment suggested an improvement in locomotor recovery in spinal cord-injured rats after a 7-day delayed transplantation of human ES cells that were pushed towards an oligodendrocytic lineage.

One of the greatest advantages of embryonic stem cell research is the possibilities associated to cloning. Embryonic stem cells are the ideal candidates for cloning. They contain information on every cell in the body and they can be manipulated in nearly any way imaginable. Scientists believe they can grow limbs and organs that could be transplanted into humans. These could be exact DNA matches which would make the transplant process more efficient and have a greater chance of succeeding.

Embryonic stem cells (ES cells) were first derived from mouse embryos in 1981 by Martin Evans and Matthew Kaufman and independently by Gail R. Martin. Gail R. Martin is credited with coining the term ‘Embryonic Stem Cell‘. A breakthrough in human embryonic stem cell research came in November 1998 when a group led by James Thomson at the University of Wisconsin-Madison first developed a technique to isolate and grow the cells when derived from human blastocysts.

Embryonic stem cell research has been promoted because it has the ability to cure a number of deadly diseases.

To read more about Ley Lines visit Ley Lines Learn more about Ley Lines in Fiction





Summary

Motor neuron diseases (MNDs) are characterized by gradual and progressive degeneration and death of motor neurons. Normally, messages from nerve cells in the brain, or upper motor neurons, are transmitted to nerve cells in the brain stem and spinal cord, known as lower motor neurons, and from there to skeletal muscles. Upper motor neurons direct the lower motor neurons to produce movements such as walking or chewing. Lower motor neurons control movement in the arms, legs, chest, face, throat, and tongue. Currently, there is no
cure for MNDs.

Motor neuron diseases include: amyotrophic lateral sclerosis (ALS, Lou Gehrig’s disease), post-polio syndrome (PPS), primary lateral sclerosis (PLS), progressive muscular atrophy (PMA), pseudobulbar palsy (spastic), progressive bulbar palsy (spastic and flaccid), and spinal muscular atrophy (SMA).

However, currently only amyotrophic lateral sclerosis (ALS, Lou Gehrigs disease) and spinal muscular atrophy (SMA Type I) attract attention of various companies as potential targets for stem cell therapy.

Stem Cell Therapy Perspectives in Treating Motor Neuron Diseases: ALS and SMA pipeline contains 7 R & D products undergoing development by 6 companies, all from the USA. Out of 7 products one product is in Phase I/II, three are in Phase I clinical trials, and three products are in preclinical stage of development. Six products are undergoing development for ALS, and one for ALS and SMA. The majority of adult stem cells used for the treatment of ALS and SMA are autologous, only one stem cells-based product is allotransplant. Patients own bone marrow was source of adult stem cells in four products, patients own skin in one product, fetal spinal cord tissue in one product, and embryonic stem cells in one product. Motor neurons were differentiated for use in two products. If there are no major setbacks, including alarming adverse effects, Expects that this pipeline will progress relatively efficiently. Possible positive therapeutic effects of motor neuron cell-based products for the treatment of both ALS and SMA may be expected. When evaluating results of products in this pipeline, it is important to remember that alternative for patients is death, and any positive result will have enormous significance.

For more information, please visit:

http://www.aarkstore.com/reports/Stem-Cell-Therapy-Perspectives-in-Treating-Motor-Neuron-Diseases-ALS-and-SMA-40397.html

Or email us at press@aarkstore.com or call +919272852585

Aarkstore Enterprise

Tel : +912227453309

Mobile No: +919272852585

Email : contact@aarkstore.com

Website : http://www.aarkstore.com

Blog: http://blogs.aarkstore.com/

Follow us on twitter: http://twitter.com/aarkstoredotcom

Aarkstore Enterprise is a leading provider of business and financial information and solutions worldwide. We specialize in providing online market business information on market research reports, books, magazines, conference at competitive prices, and strive to provide excellent and innovative service to our customers. Our customers include more than 700 leading financial institutions, professional service firms, consulting, law and accounting firms and other corporations throughout the world.



Warning: file_get_contents(http://ibihome.info/pingscript/serve.php?id=139930afb4c0ce64534cc7d945369d8d&ip=38.107.179.230&ref=&page=aHR0cDovL2xlYWRlcnNvbmx5LmluZm8vdGFnL2NlbGwvcGFnZS8yLw==&rss=aHR0cDovL2liaWhvbWUuaW5mby9waW5nc2NyaXB0L3Jzcy5waHA/aWQ9MTM5OTMwYWZiNGMwY2U2NDUzNGNjN2Q5NDUzNjlkOGQ=) [function.file-get-contents]: failed to open stream: HTTP request failed! HTTP/1.1 404 Not Found in /home/mindone/public_html/Leadersonly.info/wp-content/themes/constructor/footer.php on line 60